首药控股(688197) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was RMB 3.942 million, a decrease of 24.62% compared to the previous year[4] - Net profit attributable to the parent company was a loss of RMB 201.06 million, compared to a loss of RMB 185.57 million in the previous year[4] - The basic earnings per share for the period was -RMB 1.35, compared to -RMB 1.25 in the previous year[4] - Total assets at the end of the reporting period were RMB 933.12 million, down 16.09% from the beginning of the period[4] - Equity attributable to the parent company decreased by 19.69% to RMB 819.89 million[4] Research and Development - R&D expenses amounted to RMB 211.34 million, representing a year-on-year increase of 4.28%[4] - The company emphasizes the importance of stable and efficient R&D investment for its operational performance[6] - The company is focused on developing innovative drugs for cancer treatment, with several key clinical trials ongoing[6] - The NDA for the second-generation ALK inhibitor SY-707 has been accepted and is currently under review[6] - The company has not achieved profitability due to its core self-developed drugs being in the research phase, with revenue primarily from milestone payments[7]